China bribe probe hits first big domestic pharma target
This article was originally published in Scrip
Executive Summary
Perceptions that China's large state-owned pharma conglomerates might be politically immune from the ongoing corruption probes in the sector and elsewhere have been shattered by the disclosure that two executives of the huge Sinopharm Group are under investigation.